2型糖尿病中使用钠-葡萄糖协同转运蛋白2抑制剂和胰高血糖素样肽1受体激动剂的糖尿病视网膜病变与糖尿病黄斑水肿风险:基于全球联邦数据库的真实世界数据研究
结果显示SGLT2i+胰岛素与较低的糖尿病黄斑水肿风险相关(HR 0.835),而GLP1-ra+胰岛素与糖尿病视网膜病变风险升高相关(HR 1.308)。作者认为需使用专用视网膜成像的随机对照试验来确定因果关系。
要点
- SGLT2i+胰岛素与糖尿病黄斑水肿风险降低相关(HR 0.835;95%CI 0.780, 0.893)。
- GLP1-ra+胰岛素与糖尿病视网膜病变风险升高相关(HR 1.308;95%CI 1.261, 1.357)。
- 与SGLT2i+胰岛素相比,GLP1-ra+胰岛素与更高的视网膜病变和黄斑水肿风险相关。
核心结论
- SGLT2i与胰岛素联用与较低的糖尿病黄斑水肿发生风险相关。
- GLP1-ra与胰岛素联用与接受胰岛素治疗的2型糖尿病患者糖尿病视网膜病变风险升高相关。
- 对比分析显示SGLT2i+胰岛素在糖尿病黄斑水肿和糖尿病视网膜病变方面结局更有利。
- 需要采用专用视网膜成像的随机对照试验来确定这些治疗与结局的因果关系。
研究设计与样本
- 干预队列为SGLT2i+胰岛素(n=176,409)和GLP1-ra+胰岛素(n=207,034),对照队列为胰岛素未联用SGLT2i/GLP1-ra(n=1,922,312)。
- 采用Kaplan-Meier生存分析并报告各结局的估计HR。
- 使用倾向评分按年龄、性别、缺血性心脏病、高血压、微血管并发症、慢性肾脏病、HbA1c、BMI及吡格列酮、调脂药、抗血脂药、ACE抑制剂、血管紧张素II抑制剂和二甲双胍使用进行1:1匹配。
- 还进行了两个干预队列之间的亚组分析。
主要发现
- 与对照队列相比,SGLT2i+胰岛素与糖尿病黄斑水肿风险降低相关(HR 0.835;95%CI 0.780, 0.893)。
- 与对照队列相比,GLP1-ra+胰岛素与糖尿病黄斑水肿风险无统计学显著关联(HR 1.013;95%CI 0.960, 1.069)。
- 与对照队列相比,SGLT2i+胰岛素与糖尿病视网膜病变风险无临床显著增加相关(HR 1.076;95%CI 1.027, 1.127)。
- 与对照队列相比,GLP1-ra+胰岛素与糖尿病视网膜病变风险升高相关(HR 1.308;95%CI 1.261, 1.357)。
- 与SGLT2i+胰岛素相比,GLP1-ra+胰岛素与更高的糖尿病视网膜病变风险(HR 1.205;95%CI 1.153, 1.259)和糖尿病黄斑水肿风险(HR 1.130;95%CI 1.056, 1.208)相关。
局限性
- 需要采用专用视网膜成像的随机对照试验来确定这些治疗与结局的因果关系。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: A protective role of sodium-glucose cotransporter 2 inhibitors (SGLT2is) and glucagon-like peptide 1 receptor agonists (GLP1-ra) in the development of diabetic retinopathy and diabetic macular oedema has been described in some recent studies, which may extend beyond glycaemic control. We aimed to review the clinical impact of SGLT2i and GLP1-ra therapy on the risk of diabetic retinopathy and diabetic macular oedema in individuals with type 2 diabetes taking insulin. METHODS: This is a retrospective cohort analysis of approximately two million people with type 2 diabetes receiving insulin across 97 healthcare organisations using a global federated health research network (TriNetX, Cambridge, USA). Two intervention cohorts (SGLT2i + insulin, n=176,409; GLP1-ra + insulin, n=207,034) were compared against a control cohort (insulin with no SGLT2i/GLP1-ra, n=1,922,312). Kaplan-Meier survival analysis was performed and estimated HRs were reported for each outcome. Propensity score was used to 1:1 match for age, sex, ischaemic heart disease, hypertension, microvascular complications, chronic kidney disease, HbA1c, BMI and use of pioglitazone, lipid modifying agents, antilipemic agents, ACE inhibitors, angiotensin II inhibitors and metformin. A sub-analysis comparing the two intervention cohorts was also performed. RESULTS: SGLT2i with insulin was associated with a reduced HR (95% CI) for diabetic macular oedema compared with the control cohort (0.835; 0.780, 0.893), while GLP1-ra with insulin demonstrated a lack of signal with no statistical significance to the HR (1.013; 0.960, 1.069). SGLT2i with insulin was not associated with a clinically significant increase in the risk of developing diabetic retinopathy (1.076; 1.027, 1.127), while GLP1-ra with insulin increased diabetic retinopathy risk (1.308; 1.261, 1.357). Compared with SGLT2i with insulin, GLP1-ra with insulin was associated with higher risk of diabetic retinopathy (1.205; 1.153, 1.259) and diabetic macular oedema (1.130; 1.056, 1.208). CONCLUSIONS/INTERPRETATION: Our study suggests that the combination of SGLT2i and insulin is associated with lower risk of developing diabetic macular oedema. However, the use of GLP1-ra was associated with an increased risk of diabetic retinopathy in individuals with type 2 diabetes also taking insulin. A comparative analysis showed favourable outcomes with SGLT2i and insulin in the development of diabetic macular oedema and diabetic retinopathy. RCTs using dedicated retinal imaging are required to determine the causal relationship with these therapies.
引用
- Eleftheriadou A, Riley D, Zhao SS, et al. Risk of diabetic retinopathy and diabetic macular oedema with sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists in type 2 diabetes: a real-world data study from a global federated database. Diabetologia. 2024. PMID: 38584180. doi:10.1007/s00125-024-06132-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。